Caribou Biosciences Inc (CRBU) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Caribou Biosciences Inc stock (CRBU) is currently trading at $1.82. Caribou Biosciences Inc PS ratio (Price-to-Sales) is 16.19. Analyst consensus price target for CRBU is $11.12. WallStSmart rates CRBU as Sell.
- CRBU PE ratio analysis and historical PE chart
- CRBU PS ratio (Price-to-Sales) history and trend
- CRBU intrinsic value — DCF, Graham Number, EPV models
- CRBU stock price prediction 2025 2026 2027 2028 2029 2030
- CRBU fair value vs current price
- CRBU insider transactions and insider buying
- Is CRBU undervalued or overvalued?
- Caribou Biosciences Inc financial analysis — revenue, earnings, cash flow
- CRBU Piotroski F-Score and Altman Z-Score
- CRBU analyst price target and Smart Rating
Caribou Biosciences Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Caribou Biosciences Inc (CRBU) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Caribou Biosciences Inc (CRBU) Key Strengths (2)
Revenue surging 89.70% year-over-year
Trading at 1.48x book value, attractively priced
Supporting Valuation Data
Caribou Biosciences Inc (CRBU) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Very expensive at 16.2x annual revenue
Micro-cap company with very limited liquidity and high volatility
Moderate institutional interest at 37.70%
Supporting Valuation Data
Caribou Biosciences Inc (CRBU) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Price/Book. Valuation metrics including Price/Book (1.48) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 89.70%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (16.19) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -79.00%, Operating Margin at -722.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -79.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 89.70% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CRBU Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CRBU's Price-to-Sales ratio of 16.19x trades at a deep discount to its historical average of 45.2x (32th percentile). The current valuation is 92% below its historical high of 204.01x set in Aug 2021, and 264% above its historical low of 4.45x in Jun 2024. Over the past 12 months, the PS ratio has expanded from ~8.8x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Caribou Biosciences Inc (CRBU) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Caribou Biosciences Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 11M with 90% growth year-over-year.
Key Findings
Revenue growing at 90% YoY, reaching 11M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Debt-to-equity ratio of 0.18 indicates a conservative balance sheet with 11M in cash.
Free cash flow is -21M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Caribou Biosciences Inc maintain 90%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 2.55, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Caribou Biosciences Inc.
Bottom Line
Caribou Biosciences Inc is a high-conviction growth story with revenue accelerating at 90% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(24 last 3 months)
| Insider | Type | Shares |
|---|---|---|
KELLY, TIMOTHY P Chief Technology Officer | Sell | -6,228 |
Data sourced from SEC Form 4 filings
Last updated: 11:52:42 AM
About Caribou Biosciences Inc(CRBU)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Caribou Biosciences Inc. is a pioneering biotechnology company specializing in the development of CRISPR-based therapies for genetic disorders and cancer. Leveraging its proprietary genome-editing technology, Caribou is dedicated to advancing precision medicine through a robust pipeline of innovative product candidates that address significant unmet medical needs. With a network of strategic partnerships enhancing its research capabilities, the company is well-positioned to make a transformative impact in the biopharmaceutical sector, ultimately striving to redefine treatment paradigms and improve patient outcomes.